Stock Events

Stock Events

Grey Matters Health 

$0.33
13
+$0.01+1.9% Friday 15:27

Statistics

Day High
0.32
Day Low
0.29
52W High
0.71
52W Low
0.23
Volume
642
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24JulExpected
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q4 2025
Q1 2026
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-382,644.02Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGNPF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap28.61B
Biogen focuses on neurology, a field relevant to Algernon Pharmaceuticals' interest in neurological diseases, making them direct competitors in research and development of treatments.
Lilly(Eli) &
LLY
Mkt Cap949.7B
Eli Lilly and Company has a strong portfolio in neuroscience and psychiatric medications, areas that Algernon Pharmaceuticals is also exploring, positioning them as competitors.
Pfizer
PFE
Mkt Cap147.62B
Pfizer has a broad range of pharmaceutical products, including treatments for conditions that Algernon Pharmaceuticals is targeting, making them competitors in multiple therapeutic areas.
Merck
MRK
Mkt Cap302.33B
Merck & Co., Inc. competes in the development of drugs for diseases that Algernon Pharmaceuticals is also interested in, such as neurological and respiratory diseases.
Novartis
NVS
Mkt Cap290.05B
Novartis AG has a diversified portfolio, including treatments for neurological conditions, directly competing with Algernon Pharmaceuticals' research interests.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences, Inc. is involved in the development of treatments for viral infections, an area that Algernon Pharmaceuticals has shown interest in, making them competitors.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie Inc. works on neuroscience among other areas, directly competing with Algernon Pharmaceuticals in the development of treatments for neurological conditions.
AMGEN
AMGN
Mkt Cap183.12B
Amgen Inc. has a focus on innovative therapeutics, including areas that overlap with Algernon Pharmaceuticals' interests, positioning them as competitors.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap39.67B
Teva Pharmaceutical Industries Limited operates in generic and specialty medicines, including areas of interest to Algernon Pharmaceuticals, making them indirect competitors.
Johnson & Johnson
JNJ
Mkt Cap564.11B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in various therapeutic areas, including those targeted by Algernon Pharmaceuticals, making them a broad competitor.

About

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Christopher J. Moreau
Employees
5
Country
United States
ISIN
CA3978841078

Listings

CN
CA
GREY.CN
MU
DE
AGW0.MU
STU
DE
AGW0.STU
CN
CA
AGN.CN

0 Comments

Share your thoughts

FAQ

What is Grey Matters Health stock price today?▼
The current price of AGNPF is $0.33 USD — it has increased by +1.9% in the past 24 hours. Watch Grey Matters Health stock price performance more closely on the chart.
What is Grey Matters Health stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Grey Matters Health stocks are traded under the ticker AGNPF.
Is Grey Matters Health stock price growing?▼
AGNPF stock has risen by +14.8% compared to the previous week, the month change is a +4.87% rise, over the last year Grey Matters Health has showed a -41.66% decrease.
When is the next Grey Matters Health earnings date?▼
Grey Matters Health is going to release the next earnings report on July 24, 2026.
What is Grey Matters Health revenue for the last year?▼
Grey Matters Health revenue for the last year amounts to 0 USD.
What is Grey Matters Health net income for the last year?▼
AGNPF net income for the last year is -382,644.02 USD.
How many employees does Grey Matters Health have?▼
As of May 30, 2026, the company has 5 employees.
In which sector is Grey Matters Health located?▼
Grey Matters Health operates in the Health & Wellness sector.
When did Grey Matters Health complete a stock split?▼
The last stock split for Grey Matters Health was on April 21, 2026 with a ratio of 1:10.
Where is Grey Matters Health headquartered?▼
Grey Matters Health is headquartered in Vancouver, United States.